APA

Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M. & Kotoula V. (20171226). TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. : Oncotarget.

Chicago

Fountzilas George, Giannoulatou Eleni, Alexopoulou Zoi, Zagouri Flora, Timotheadou Eleni, Papadopoulou Kyriaki, Lakis Sotiris, Bobos Mattheos, Poulios Christos, Sotiropoulou Maria, Lyberopoulou Aggeliki, Gogas Helen, Pentheroudakis George, Pectasides Dimitrios, Koutras Angelos, Christodoulou Christos, Papandreou Christos, Samantas Epaminontas, Papakostas Pavlos, Kosmidis Paris, Bafaloukos Dimitrios, Karanikiotis Charisios, Dimopoulos Meletios-Athanassios and Kotoula Vassiliki. 20171226. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. : Oncotarget.

Harvard

Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M. and Kotoula V. (20171226). TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. : Oncotarget.

MLA

Fountzilas George, Giannoulatou Eleni, Alexopoulou Zoi, Zagouri Flora, Timotheadou Eleni, Papadopoulou Kyriaki, Lakis Sotiris, Bobos Mattheos, Poulios Christos, Sotiropoulou Maria, Lyberopoulou Aggeliki, Gogas Helen, Pentheroudakis George, Pectasides Dimitrios, Koutras Angelos, Christodoulou Christos, Papandreou Christos, Samantas Epaminontas, Papakostas Pavlos, Kosmidis Paris, Bafaloukos Dimitrios, Karanikiotis Charisios, Dimopoulos Meletios-Athanassios and Kotoula Vassiliki. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. : Oncotarget. 20171226.